An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis

Trial Profile

An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs ATA 188 Allogeneic (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 05 Mar 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2020.
    • 10 Jan 2018 According to an Atara Biotherapeutics media release, the company anticipates the first results from the study in the first half of 2019.
    • 10 Jan 2018 According to an Atara Biotherapeutics media release, the company has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to proceed with patient enrollment at U.S. sites. Patient enrollment at U.S. sites beginning in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top